165 results
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
include research and development (“R&D”) costs and general and administrative (“G&A”) expenses, were $4.0 million in the Fiscal 2024 Quarter, compared … difference in other items of income and expense were the non-cash losses on impairment relating to the carrying value of in-process research and development
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
-current assets
Investment in associate
Investment in public company
In-process research and development
Deferred commitment fee, net … Months Ended
December 31,
Expenses
Research and development
General and administrative expenses
Loss from operations
Change in fair value of deferred
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
receivable
Total current assets
Non-current assets
Investment in associate
Investment in public company
In-process research and development …
Three Months EndedDecember 31,
Nine Months EndedDecember 31,
Expenses
Research and development
General and administrative expenses
Loss from operations
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
shares of Stimunity, the subsidiary on which the PORT-5 platform is managed.
Early-Stage Research and Development Collaborations
We continue … with such equity financing in October 2023.
A non-cash loss on impairment of $46.9 million with respect to the iOx in-process research and development (“IPR
424B3
PRTG
Portage Biotech Inc
28 Nov 23
Prospectus supplement
4:03pm
in public company
In-process research and development
9, 10
Deferred commitment fee
Right to use asset
Other assets, including equipment, net
Total non … Ended
September 30,
Six Months Ended
September 30,
Expenses
Research and development
General and administrative expenses
Loss from operations
Change
6-K
EX-99.1
o21p0oc9c
28 Nov 23
PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
4:02pm
6-K
EX-99.1
7clfkh ud
28 Nov 23
Current report (foreign)
4:01pm
6-K
EX-99.2
y0vt6ro7zpcht8r
28 Nov 23
Current report (foreign)
4:01pm
424B3
n40qva 3w4ab
7 Nov 23
Prospectus supplement
4:50pm
F-1
tzomnc znnvw3haoe29f
31 Oct 23
Registration statement (foreign)
4:05pm
424B5
5rfaclyf06v6vw0r8n
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.1
qfvmn6rj
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
b3a3vxj
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.1
o2l87 t8wajs
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.1
tkg 3ek0l6hqdo0ajk
31 Jul 23
Current report (foreign)
6:10pm